Breakthrough Summit West: AI, Longevity, and Biotech Insights

Leaders from the science and health care sectors recently convened at STAT’s Breakthrough Summit West to discuss the evolving landscape of drug development, research transparency, and the pursuit of human longevity.

Among the key discussions was the role of artificial intelligence in accelerating the creation of new medicines. Joe Betts-LaCroix, the CEO of Retro Biosciences, discussed the company’s efforts to determine the specific impact AI can have on the drug development process.

Retro Biosciences, a longevity-focused company backed by Sam Altman, is currently preparing for its first clinical data readout. This milestone will provide initial insights into the company’s approach to extending human healthspan.

Research Transparency and Publication Standards

The summit also addressed the technicalities of how scientific findings are shared with the broader medical community. Neil Kumar, the CEO of BridgeBio, raised concerns regarding the way the company has presented its data.

Kumar noted that BridgeBio has been publishing not the right structures within its research publications, suggesting a need for better frameworks in reporting scientific results.

Broader Biotech Trends

The conversations at the event highlighted a dual focus on high-stakes innovation and the security of the biotechnology sector. Discussions centered on the strategic necessity of guarding biotech interests while simultaneously placing large bets on longevity science.